Join STRIVE Study for Early Cancer Detection

Join 120,000 women in the STRIVE Study to help detect cancer early.
Thirty minutes of your time could help make available a new blood test for detecting breast cancer.






Get Started

The purpose of the STRIVE Study is to evaluate an exciting, new option for detecting breast cancer early. This new technology, developed by GRAIL, uses a blood test to find small pieces of DNA released into the blood by tumors. The earlier that breast cancer can be found, the higher the chance of a cure.

This study will look at whether a blood test, possibly in combination with other information, could do a better job at finding cancers than current screening methods. This blood test may also be able to find other types of cancer early. The study will serve as an important resource for understanding the biology of cancer development.

The study is currently open to women who are scheduled for a screening mammogram at select Sarah Cannon Cancer Institute locations. Click the link below for more information and a list of participating locations.